Study identifier:NIS-GVN-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Epidemiological survey to describe impact of reflux disease on everyday life in GERD patients before and after 4 weeks treatment
Gastroesophageal Reflux Disease
-
No
-
All
2091
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment group; and to describe the concordance between patient-reported and physician-reported symptom load.
Location
Location
Ban Me Thuot, Dac Lac, Vietnam
Location
Bien Hoa, Dong Nai, Vietnam
Location
Ca mau, Vietnam
Location
Can Tho, Vietnam
Location
Cao Lanh, Dong Thap, Vietnam
Location
Danang, Vietnam
Location
Haiphong, Vietnam
Location
Hanoi, Vietnam
Arms | Assigned Interventions |
---|---|
1 GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.